<- Go Home
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Market Cap
$1.1B
Volume
220.3K
Cash and Equivalents
$100.6M
EBITDA
-$98.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$30.03
52 Week Low
$10.90
Dividend
N/A
Price / Book Value
3.55
Price / Earnings
-11.42
Price / Tangible Book Value
3.55
Enterprise Value
$767.5M
Enterprise Value / EBITDA
-7.82
Operating Income
-$99.1M
Return on Equity
30.98%
Return on Assets
-21.37
Cash and Short Term Investments
$291.8M
Debt
$85.0K
Equity
$288.4M
Revenue
N/A
Unlevered FCF
-$38.6M
Sector
Pharmaceuticals
Category
N/A